Onconova Therapeutics (ONTX) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings or view top-rated stocks.

Onconova Therapeutics' stock was trading at $0.6457 at the start of the year. Since then, ONTX shares have increased by 85.8% and is now trading at $1.20.
View the best growth stocks for 2023 here.

Onconova Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 291,400 shares, a drop of 24.8% from the April 30th total of 387,400 shares. Based on an average daily volume of 540,800 shares, the days-to-cover ratio is currently 0.5 days.
View Onconova Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ONTX earnings forecast.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its quarterly earnings data on Thursday, March, 16th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. The biopharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.08 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 67.03% and a negative net margin of 9,122.57%.

Onconova Therapeutics shares reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Onconova Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.69%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Mark Patrick Guerin and Steven M Fruchtman.
View institutional ownership trends.

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ONTX stock can currently be purchased for approximately $1.20.

Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $25.16 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-18,960,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for the company is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681.